Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01810627

Enrollment

Registered

2013-03-13

Start date

2013-09-30

Completion date

2016-04-30

Last updated

2017-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate, Cancer

Brief summary

This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

Interventions

RADIATIONMVCT

Patients will receive an additional MVCT scan at their one month follow up visit.

Eligibility

Sex/Gender

MALE

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

Male 50-80 years of age Eligible for interstitial brachytherapy implants

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Change in prostate volume measured in cm^3	One month post implant	Change in prostate volume measured with trans-rectal ultrasound at baseline versus prostate volume measured with KVCT and MVCT.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026